Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19585072 | 0.98 | CHKA (0.59) | CHKAKDM4ESMN1; SMN2MAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL10900610 | 0.98 | CHKA (0.59) | CHKAKDM4ESMN1; SMN2MAPK1MEN1 | |
| SCHEMBL5038790 | 0.98 | CHKA (0.59) | CHKAKDM4ESMN1; SMN2MAPK1MEN1 | |
| SCHEMBL3036998 | 0.94 | CHKA (0.62) | CHKAKDM4ESMN1; SMN2MAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL20305004 | 0.93 | CXCR4 (0.62) | CHKAKDM4ESMN1; SMN2MAPK1MEN1 | |
| Tert-Butyl Formate SCHEMBL28272976 | 0.89 | CHKA (0.50) | CHKAKDM4ESMN1; SMN2MAPK1MEN1 | |
| SCHEMBL5026403 | 0.87 | KDM4E (0.50) | CHKAKDM4ESMN1; SMN2MAPK1MEN1 | |
| SCHEMBL2873979 | 0.86 | CHKA (0.72) | CHKAKDM4ESMN1; SMN2MAPK1MEN1 | |
| SCHEMBL20210248 | 0.86 | CHKA (0.77) | CHKAKDM4ESMN1; SMN2MAPK1MEN1 | |
| SCHEMBL10568920 | 0.85 | LMNA (0.58) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105001205-A | Preparation method of imatinib impurity D | QILU TIANHE PHARMACEUTICAL CO LTD | 2015-10-28 | — | — | CN | claimed |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250250266-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250136614-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | MAGICBULLETTHERAPEUTICS CO., LTD. (KR) | 2025-05-01 | — | — | US | disclosed |
| EP-4442691-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | Magicbullettherapeutics Co., Ltd. (KR) | 2024-10-09 | — | — | EP | disclosed |
| CN-113072542-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11725005-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| CN-116535343-A | Hydroxamic acid compound and application thereof | 温州医科大学 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023140629-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | 닥터아이앤비(주) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023101387-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | 연세대학교 산학협력단 | 2023-06-08 | — | — | WO | disclosed |
| EP-1874315-A2 | COMPOSITIONS OF NOVEL OPIOID COMPOUNDS AND METHOD OF USE THEREOF | Mount Cook Biosciences, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1685094-A4 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S BIO PTE LTD (SG) | 2007-08-22 | — | — | EP | disclosed |
| CN-1310911-C | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2007-04-18 | — | — | CN | disclosed |
| US-20070043028-A1 | Compositions of novel opioid compounds and method of use thereof | DMK PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
| WO-2006113468-A2 | COMPOSITIONS OF NOVEL OPIOID COMPOUNDS AND METHOD OF USE THEREOF | MOUNT COOK BIOSCIENCES, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1685094-A1 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S*Bio Pte Ltd (SG) | 2006-08-02 | — | — | EP | disclosed |
| CN-1662528-A | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-31 | — | — | CN | disclosed |
| WO-2005040101-A1 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040101-A1 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
| US-4616086-A | ANTICOAGULANTS | BOEHRINGER MANNHEIM GMBH (DE) | 1986-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136614-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | STK25, MAP3K15, MAP3K5 | CHKA 1403/4885KDM4E 2242/4885SMN1; SMN2 3150/4885 |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | PTK2, HCK, PTK2B | CHKA 11/4885KDM4E 2732/4885SMN1; SMN2 1120/4885 |
| US-20070043028-A1 | Compositions of novel opioid compounds and method of use thereof | OPRL1, OPRD1, OPRK1 | CHKA 1366/4885KDM4E 3019/4885SMN1; SMN2 1087/4885 |
| US-20250250266-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | CHKA 180/4885KDM4E 1589/4885SMN1; SMN2 4333/4885 |
| US-11725005-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | CHKA 180/4885KDM4E 1589/4885SMN1; SMN2 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.